


DESCRIPTIVE REAL-WORLD OUTCOMES WITH AFLIBERCEPT 8 MG/0.07 ML IN WET AMD AND DME

E. GANDULLO SANCHEZ, A.C. RODRÍGUEZ NEGRÍN, C. ESPIN MARTINEZ, V. GARCIA NAVARRO, C. BORDES DOMINGUEZ DEL RIO,
J. GODOY GONZALEZ, C.L. CRESPO MARTINEZ.

HOSPITAL PHARMACY DEPARTAMENT, COMPLEJO HOSPITALARIO UNIVERSITARIO INSULAR MATERNO-INFANTIL, LAS PALMAS DE
GRAN CANARIA (SPAIN).

Background and Importance

Aflibercept recombinant fusion protein




- Functions as a **receptor binding vascular endothelial growth factor-A and placental growth factor**
- Greater affinity** than their natural receptors

2024

Marketed at a **dose of 8 mg/0.07 mL**

Therapeutic indications

- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)



Aim and Objectives

To evaluate the use of aflibercept 8 mg/0.07 mL in real-world clinical practice in patients with wet AMD and DME, both naïve patients and previously treated

Materials and Methods

Unicenter, observational, descriptive and retrospective study from November 2024 to September 2025

- Age
- Sex
- Diagnosis
- Previous treatments
- Number of doses and frequency
- Reasons for discontinuation
- Side effects

After 3 monthly loading doses, if there is an improvement outcomes treatment intervals can be extended to



4 weeks up (Q8)
12 (Q12) or
16 (Q16) weeks

Previously treated patients could follow a **treat-and-extend regimen directly**

Data were extracted from medical records



Results

566 patients


♂ **56%**

71±11 years

775 eyes

42% AMD (327 eyes)

58% DME (443 eyes)



2 patients reported adverse events
reduced visual acuity, ocular pain, and blurred vision



Conclusion and relevance

- ✓ **Aflibercept 8 mg/0.07 mL** showed **effective outcomes and good tolerance** in both naïve and previously treated eyes with wet AMD and DME
- ✓ **In our real-world practice, most patients remain on Q8 intervals**, with few yet reaching Q16–Q20 extensions as described in the product label
- ✓ **Continued follow-up is needed** to assess **longer-term interval outcomes**

